Lilly’s new product was approved by the ... Both products are priced at a similar level to the glucagon injection kits available on the market, with a list price of $280 per dose, and in the ...
Eli Lilly’s intranasal formulation of glucagon – called Baqsimi – is the first alternative to injectable glucagon for severe hypoglycaemia, which typically occurs when people with diabetes ...
The format is potentially more convenient than traditional glucagon kits from the likes of Fresenius Kabi and Amphastar, but Xeris has struggled to penetrate the vast opportunity. Xeris said it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback